Aprile Strategies to overcome resistance in NSCLC with driver mutations Piano Generale di Emergenza Federico Cappuzzo Presidio Ospedaliero di Livorno Istituto Toscano Tumori Ospedale Civile Viale Alfieri 36 Livorno-Italy 2 First-line therapy for metastatic NSCLC in 2012 Stratification for EGFR, ALK and histology EGFR mutated EGFR-TKI ALK+ Crizotinib EGFR WT nonsquamous EGFR WT squamous Platinum + pemetrexed +/bevacizumab Platinumbased doublet Mut+ NSCLC: EGFR-TKI Acquired Resistance Baseline Tumor regression (RR up to 90%) Progression (median 9 months) Disease Flare: Hospitalization and/or death attributable to disease progression after discontinuation of gefitinib or erlotinib and before initiation of study drug Risk of disease flare in EGFR mut+ NSCLC with acquired resistance: Chaft J et al. (O 19.05) Characteristic: Total patients=61 Male sex – N (%) N (% or range) 13 (21) Age at diagnosis (years) Median (range) 58 (26-78) EGFR mutation – N (%) Exon 19 deletion Exon 18 G719A Exon 21 L858R 41 (67) 1 (2) 19 (31) Time on gefitinib or erlotinib (months) Median (range) 19 (7-78) Age in years - Median (Range) 61 (27-80) Karnofsky Performance Status (%) 90% 80% 70% 13 (21) 37 (61) 11 (18) • 14 of 61 patients (23%, 95% CI 14-35%) had a disease flare (hospitalization or death) – Flare & no flare group – same 30 day pretrial hospitalization rate • Median time from last TKI to flare was 8 days (range 3-21 days) • 3 patients went on to trial treatment Changes in Tumor Diameter (RECIST) After Discontinuation and Re-introduction of EGFR TKI Change from baseline 50% 20% 0% -30% EGFR TKI re-start stop 3 weeks 3 weeks Riely et al, CCR 2007 Mechanisms responsible for EGFR-TKI resistance Sequist et al, Science Transl Med 2011 EGFR-TKI resistance A B T790M Mutation causes drug resistance by increasing affinity for ATP Yun PNAS 2008 T790M mutations in EGFR-TKI naive NSCLC • Present in up to 50% of NSCLC with EGFR-TKI acquired resistance • Rare event in EGFR-TKI naive NSCLC (<3%) using low sensitive methods • Detected in up to 40% of EGFR-TKI naive patients using high sensitive methods Presence of T790M mutation predicts poor outcome to EGFR-TKI Su et al. JCO 2012; Rosell et al. Clin Cancer Res 2011; T790M mutation and acquired resistance to gefitinib therapy Irreversible EGFR-TKI are still effective Kobayashi et al. NEJM, 352, 786-792, 2005 Afatinib: Dual irreversible EGFR-HER2 inhibitor • Orally bioavailable, small molecule tyrosine kinase inhibitor (TKI) Afatinib • Designed to irreversibly bind to the ATP binding pocket of EGFR and HER2 • Highly specific for EGFR and HER2 EGFR IC50: 0.50 nM HER2 IC50: 14 nM EGFR or HER2 + ATP binding pocket Afatinib: active against resistance mutation BIBW2992 but not erlotinib is active against cells expressing T790M EGFR mutation: NCI-H1975 Li et al. Oncogene. 2008;27:4702–4711 Afatinib + cetuximab as the best option in presence of EGFR T790M mutation Regales et al. JCI 2009 Afatinib + cetuximab for metastatic NSCLC: Study Design Phase Ib, open-label, multicenter trial in the US and The Netherlands NSCLC with EGFR mutation1 Dose escalation schema 3–6 patients per cohort OR Afatinib p.o. daily + escalating doses of i.v. cetuximab q 2 weeks SD 6 months with erlotinib/gefitinib OR Partial or complete response to erlotinib/gefitinib Disease progression2 Stop erlotinib/ gefitinib for ≥72 hours3 Dose levels starting at: afatinib 40 mg + cetuximab 250 mg/m2 Predefined maximum dose: afatinib 40 mg + cetuximab 500 mg/m2 MTD cohort expanded up to 80 EGFR mutation-positive patients4: 40 T790M+ and 40 T790M– 1EGFR G719X, exon 19 deletion, L858R, L861Q; 2Progression of disease (Response Evaluation Criteria in Solid Tumors v1.1) on continuous treatment with erlotinib or gefitinib within the last 30 days; 3Amended from original 14-day interval; 4Acquisition of tumor tissue after the emergence of acquired resistance was mandated. i.v.=intravenous; MTD=maximum tolerated dose; NSCLC=non-small cell lung cancer; SD=stable disease. Tumor Regression by T790M Mutation Status at Recommended Dose 39 patients with proven EGFR T790M mutation: confirmed RR=31% Acquired resistance to EGFR-TKIs • Acquired drug resistance is almost inevitable (~10 months) • About 30% of resistant mechanisms are unknown. Mitsudomi, et al. Cancer Sci., 2007 Resistant mechanisms in 33 tumors from 6 patients with EGFR-TKI acquired resistance Tumors with T790M Number of Tumors Tumors without T790M <2.0 2.0 - 4.0 < 4.0 MET gene copy numbers (folds) Suda et al. Clin Cancer Res 2010 Inhibition of both EGFR and MET is necessary for growth inhibition of HCC827 GR cells 125 Gefitinib PHA665752 Gefitinib/PHA665752 % of control 100 75 50 25 0 0 0.01 0.1 Drug Concentration ( 1 10 μ M) • Irreversible EGFR inhibitors have no effect on HCC827 GR • MET shRNA restores sensitivity to gefitinib Engelman et al. Science 2007 EML4-ALK fusion oncogene in NSCLC 3–7% of patients with NSCLC have an EML4-ALK gene fusion1 detection test available mainly seen in adenocarcinomas (mutually exclusive with EGFR mutations)2 phase I/II trial of crizotinib, oral c-MET and ALK inhibitor in selected patients: DCR = 70%3 further potential for personalising therapy in NSCLC 1. Koivunen, et al. Clin Cancer Res 2008 2. Shaw, et al. ASCO 2009; 3. Bang, et al. ASCO 2010 ALK secondary mutations and crizotinib resistance Sasaki et al. Cancer Res 2011 New ALK inhibitors TAE684 and AP26113 overcome crizotinib resistance in H3122 CR cell line Katayama et al. PNAS 2011 Cell lines with ALK secondary mutation and ALK and EGFR co-dependency Sasaki et al. Cancer Res 2011 ALK amplification or ALK FISH loss as mechanisms of crizotinib resistance Katayama et al. PNAS 2011, Katayama et al Science Transl Med 2012, Doebele et al. Clin Cancer Res 2012 Several mechanisms responsible for crizotinib resistance: clinical implications Doebele et al. Clin Cancer Res 2012 Conclusions • Different mechanisms are responsible for acquired resistance to novel targeted therapies • So far no proven efficacy of irreversible EGFR-TKIs in NSCLC with acquired resistance to reversible agents • No clinically available strategies for crizotinib resistant patients • New drugs and new strategies are under investigation